Outcomes in HeartMate II Patients With No Antiplatelet Therapy: 2-Year Results From the European TRACE Study

Annals of Thoracic Surgery

Volumn 103, Issue 4, 2017, Pages 1262-1268

  Netuka, Ivan ^a,h   Litzler, Pierre Yves ^b   Berchtold Herz, Michael ^c   Flecher, Erwan ^d   Zimpfer, Daniel ^e   Damme, Laura ^f   Sundareswaran, Kartik S ^f   Farrar, David J ^f   Schmitto, Jan D ^g  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b HÔPITAL CHARLES NICOLLE   (France)

^c UNIVERSITY OF FREIBURG   (Germany)

^d PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY OF VIENNA   (Austria)

^f St Jude Medical Inc   (United States)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FLUINDIONE; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; ASSISTED CIRCULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; FEMALE; FOLLOW UP; HOSPITAL READMISSION; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LEFT VENTRICULAR ASSIST DEVICE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; POSTOPERATIVE PERIOD; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUMP THROMBOSIS; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; ADOLESCENT; CLINICAL TRIAL; COHORT ANALYSIS; EUROPE; HEART ASSIST DEVICE; HEART FAILURE; MORTALITY; POSTOPERATIVE HEMORRHAGE; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; COHORT STUDIES; EUROPE; FEMALE; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85008671009     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2016.07.072     Document Type: Article

References (22)

1. 1 Jorde, U.P., Kushwaha, S.S., Tatooles, A.J., et al. Results of the destination therapy Post-Food and Drug Administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 63 (2014), 1751–1757.
2. 2 Starling, R.C., Naka, Y., Boyle, A.J., et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 57 (2011), 1890–1898.
3. 3 Hasin, T., Marmor, Y., Kremers, W., et al. Readmissions after implantation of axial flow left ventricular assist device. J Am Coll Cardiol 61 (2013), 153–163.
4. 4 Crow, S., Chen, D., Milano, C., et al. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg 90 (2010), 1263–1269 discussion 1269.
5. 5 Crow, S., John, R., Boyle, A., et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg 137 (2009), 208–215.
6. 6 Klovaite, J., Gustafsson, F., Mortensen, S.A., Sander, K., Nielsen, L.B., Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol 53 (2009), 2162–2167.
7. 7 Meyer, A.L., Malehsa, D., Bara, C., et al. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail 3 (2010), 675–681.
8. 8 Uriel, N., Pak, S.W., Jorde, U.P., et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 56 (2010), 1207–1213.
9. 9 Bartoli, C.R., Restle, D.J., Zhang, D.M., Acker, M.A., Atluri, P., Pathologic von Willebrand factor degradation with a left ventricular assist device occurs via two distinct mechanisms: mechanical demolition and enzymatic cleavage. J Thorac Cardiovasc Surg 149 (2015), 281–289.
10. 10 Slaughter, M.S., Pagani, F.D., Rogers, J.G., et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant 29:4 Suppl (2010), S1–S39.
11. 11 Litzler, P.Y., Smail, H., Barbay, V., et al. Is anti-platelet therapy needed in continuous flow left ventricular assist device patients? A single-centre experience. Eur J Cardiothorac Surg 45 (2014), 55–59 discussion 59–60.
12. 12 Katz, J.N., Adamson, R.M., John, R., et al. Safety of reduced anti-thrombotic strategies in HeartMate II patients: a one-year analysis of the US-TRACE Study. J Heart Lung Transplant 34 (2015), 1542–1548.
13. 13 Boyle, A.J., Jorde, U.P., Sun, B., et al. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. J Am Coll Cardiol 63 (2014), 880–888.
14. 14 Backes, D., van den Bergh, W.M., van Duijn, A.L., Lahpor, J.R., van Dijk, D., Slooter, A.J., Cerebrovascular complications of left ventricular assist devices. Eur J Cardiothorac Surg 42 (2012), 612–620.
15. 15 Struber, M., Sander, K., Lahpor, J., et al. HeartMate II left ventricular assist device; early European experience. Eur J Cardiothorac Surg 34 (2008), 289–294.
16. 16 Boyle, A.J., Russell, S.D., Teuteberg, J.J., et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant 28 (2009), 881–887.
17. 17 Kushnir, V.M., Sharma, S., Ewald, G.A., et al. Evaluation of GI bleeding after implantation of left ventricular assist device. Gastrointest Endosc 75 (2012), 973–979.
18. 18 Kirkin, J.K., Naftel, D.C., Kormos, R.L., et al. Interagency Registry from Mechanically Assited Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant 33 (2014), 12–22.
19. 19 Starling, R.C., Moazami, N., Silvestry, S.C., et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 370 (2014), 33–40.
20. 20 Hoefer, D., Velik-Salchner, C., Antretter, H., Increase in left ventricular assist device thrombosis. N Engl J Med, 370, 2014, 1464.
21. 21 Schmitto, J.D., Avsar, M., Haverich, A., Increase in left ventricular assist device thrombosis. N Engl J Med 370 (2014), 1463–1464.
22. 22 Nassif, M.E., LaRue, S.J., Raymer, D.S., et al. Relationship between anticoagulation intensity and thrombotic or bleeding outcomes among outpatients with continuous-flow left ventricular assist devices. Circ Heart Fail, 9, 2016, e002680.